The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.

doi:10.1007/s00432-021-03748-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.

Journal of cancer research and clinical oncology - 1 Jun 2022

Hizal Mutlu, Bilgin Burak, Paksoy Nail, Açıkgöz Özgür, Sezer Ahmet, Gürbüz Mustafa, Ak Naziye, Yücel Şebnem, Ayhan Murat, Erol Cihan, Demirkıran Aykut, Mandel Nil Molinas, Shbair Abdallah, Gökmen İvo, Başoğlu Tuğba, Paydaş Semra, Demiray Atike Gökçen, İriağaç Yakup, Şakalar Teoman, Zeynelgil Esra, Tatlı Ali Murat, Bahçeci Aykut, Güven Deniz Can, Caner Burcu, Can Alper, Gülmez Ahmet, Karakaş Yusuf, Yalçın Bülent, Demirkazık Ahmet, Bilici Ahmet, Aydıner Adnan, Yumuk Perran Fulden, Şendur Mehmet Ali Nahit

Abstract excerpt

INTRODUCTION: Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. MATERIALS AND METHODS: This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Turkey

Source

Open in PubMed

Identifiers

PMID: 34331582
DOI: 10.1007/s00432-021-03748-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.PMID 34331582Read ↗

The Real-Life Efficacy And Safety of Osimertinib In Pretreated Advanced Non-Small Cell Lung Cancer Patients With T790M Mutation: A Turkish Oncology Group StudySemantic proximity Read ↗

The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis.Semantic proximity Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.Semantic proximity Read ↗

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.Semantic proximity Read ↗

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.Semantic proximity Read ↗

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.Semantic proximity Read ↗

Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapySemantic proximity Read ↗

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.